

Special Issue

Translational Research of Liver Cancer

Message from the Guest Editor

The incidence of livers cancers has more than tripled over the past 30 years. Significant progress has been made recently with regard to treatment options, and in addition to immunotherapies and anti-angiogenic agents, targeted therapies have been approved for specific molecular subsets. The growing number of treatment options for primary livers cancers, i.e., mainly hepatocellular carcinomas and intrahepatic cholangiocarcinomas, requires novel advances in biomarker discovery, patient stratification, and treatment sequencing more than ever. In this Special Edition, I would like to highlight cutting-edge translational work which might hopefully shed more light into the biology of primary liver cancers and also guide the necessary next steps in developing better treatment strategies for patients at all stages of liver cancer. Your translational research has significantly contributed to the field beyond pure drug development, and I would like to invite you to share your work with other colleagues around the globe. I look forward to your response.

Guest Editor

Prof. Dr. Farshid Dayyani
Hematology Oncology, University of California, Irvine, CA 92868, USA

Deadline for manuscript submissions

closed (30 April 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/102262

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)